Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flumazenil

FDA-approved product (injectable, injection), marketed as Flumazenil, Romazicon.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Flumazenil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Flumazenil. Its therapeutic class is shown instead.

WHO therapeutic group
Antidotes
FDA pharmacologic class
Benzodiazepine Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flumazenil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flumazenil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase Ⅰb Study of Remimazolam Tosylate in Healthy Volunteers

    NCT03444480 · start 2014-07-23

    Registered record
    Registry ID
    NCT03444480
    Conditions
    Anesthesia
    Interventions
    Remimazolam Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07-23
    Completion
    2014-08-16
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnesthesia
    InterventionRemimazolam Tosylate
    PhasePhase 1
    Registry statusCompleted

  • Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

    NCT02048969 · start 2014-06

    Registered record
    Registry ID
    NCT02048969
    Conditions
    Hepatic Encephalopathy; Liver Cirrhosis
    Interventions
    Flumazenil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2014-06
    Completion
    2017-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy; Liver Cirrhosis
    InterventionFlumazenil; Placebo
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865

    NCT02138500 · start 2014-05

    Registered record
    Registry ID
    NCT02138500
    Conditions
    Healthy
    Interventions
    PF-06372865; PF-06372865; PF-06372865
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-08
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-06372865; PF-06372865; PF-06372865
    PhasePhase 1
    Registry statusCompleted

  • Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis

    NCT01651520 · start 2013-06

    Registered record
    Registry ID
    NCT01651520
    Conditions
    Multiple Sclerosis
    Interventions
    PET with 11C-Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-06
    Completion
    2019-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionPET with 11C-Flumazenil
    PhaseNot applicable
    Registry statusUnknown

  • Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Brain on the Neurotransmitter Binding

    NCT01819675 · start 2013-03

    Registered record
    Registry ID
    NCT01819675
    Conditions
    Stroke; Hemiplegia
    Interventions
    Low frequency rTMS; High frequency rTMS; Sham rTMS
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2013-03
    Completion
    2016-02
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Hemiplegia
    InterventionLow frequency rTMS; High frequency rTMS; Sham rTMS
    PhaseNot applicable
    Registry statusTerminated

  • Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder

    NCT01547819 · start 2012-02-16

    Registered record
    Registry ID
    NCT01547819
    Conditions
    Posttraumatic Stress Disorder; Traumatic Brain Injury
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2012-02-16
    Completion
    2013-12-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder; Traumatic Brain Injury
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence

    NCT01904487 · start 2011-04-19

    Registered record
    Registry ID
    NCT01904487
    Conditions
    Alcoholism
    Interventions
    [11C]flumazenil; Tiagabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04-19
    Completion
    2013-10-01
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcoholism
    Intervention[11C]flumazenil; Tiagabine
    PhasePhase 1
    Registry statusCompleted

  • Flumazenil for the Treatment of Primary Hypersomnia

    NCT01183312 · start 2010-09

    Registered record
    Registry ID
    NCT01183312
    Conditions
    Hypersomnia; Primary Hypersomnia; Idiopathic Hypersomnia; Narcolepsy Without Cataplexy
    Interventions
    Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2010-09
    Completion
    2012-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypersomnia; Primary Hypersomnia; Idiopathic Hypersomnia; Narcolepsy Without Cataplexy
    InterventionFlumazenil
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Safety and Pharmacokinetic Study of Sublingual Flumazenil (CRLS035) in Healthy Adults

    NCT01655914 · start 2010-07

    Registered record
    Registry ID
    NCT01655914
    Conditions
    Insomnia
    Interventions
    Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-07
    Completion
    2012-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionFlumazenil
    PhasePhase 1
    Registry statusCompleted

  • A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder

    NCT00997087 · start 2009-10

    Registered record
    Registry ID
    NCT00997087
    Conditions
    Obsessive Compulsive Disorder
    Interventions
    Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-10
    Completion
    2012-12
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive Compulsive Disorder
    InterventionFlumazenil
    PhasePhase 2
    Registry statusTerminated

  • Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325

    NCT00681720 · start 2008-02

    Registered record
    Registry ID
    NCT00681720
    Conditions
    Anxiety
    Interventions
    AZD7325; Radioligand (11C) flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-07
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety
    InterventionAZD7325; Radioligand (11C) flumazenil
    PhasePhase 1
    Registry statusCompleted

  • Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280

    NCT00681746 · start 2008-02

    Registered record
    Registry ID
    NCT00681746
    Conditions
    Anxiety
    Interventions
    AZD6280; (11C) flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-09
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety
    InterventionAZD6280; (11C) flumazenil
    PhasePhase 1
    Registry statusCompleted

  • Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence

    NCT00570388 · start 2007-03

    Registered record
    Registry ID
    NCT00570388
    Conditions
    Alcohol Dependence
    Interventions
    Prometa Treatment Program
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2007-03
    Completion
    2008-09
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence
    InterventionPrometa Treatment Program
    PhaseNot applicable
    Registry statusUnknown

  • Brain Changes in Patients With Focal Hand Dystonia

    NCT00306865 · start 2006-03-17

    Registered record
    Registry ID
    NCT00306865
    Conditions
    Focal Dystonia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-03-17
    Completion
    2010-10-14
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFocal Dystonia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Prometa Pharmacotherapy for Methamphetamine Dependence

    NCT00260481 · start 2006-01

    Registered record
    Registry ID
    NCT00260481
    Conditions
    Drug Abuse; Drug Dependence
    Interventions
    Prometa; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2006-01
    Completion
    2008-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Abuse; Drug Dependence
    InterventionPrometa; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted